Abstract
Background: Patients with CRSwNP suffer nasal congestion, anosmia, and headaches. Data to characterize Canadians with CRSwNP are lacking.
Objective: To describe the characteristics and treatment of patients with CRSwNP in Manitoba, Canada.
Methods: A population-based cohort study (2004–2018) was conducted using linked physician billing, inpatient, and pharmacy records from Manitoba (population, 1.3). Adults with CRSwNP were identified by physician diagnosis or CRSwNP surgery codes. Baseline characteristics were summarized using means and standard deviations (SD), and comorbidity burden by Elixhauser Index (EI). The percentage treated with CRSwNP therapies over the period was tabulated.
Results: Of the 8,960 patients identified, the mean (SD) age was 49.9 (15.7) years and follow up was 7.1 (3.7) years. The mean (SD) EI was 1.1 (1.2), and hypertension (22.6%) and chronic pulmonary diseases (22.4%; including but not limited to asthma) were the most frequent baseline comorbidities. During the study period, a secondary diagnosis of comorbid asthma was identified in 33% of patients. Nearly all (98.3%) received treatment: 70.4% with intranasal steroids (INS), 47.1% oral corticosteroids (OCS), 88.3% antibiotics, and 76.9% endoscopic surgery. More than 75% required retreatment after initial therapy. Patients received a median (IQR) of 1.3 (2.1) courses of INS annually, 0.5 (0.8) of OCS, and 1.2 (1.1) of antibiotics.
Conclusions: Medical and surgical management was frequently observed in this large CRSwNP cohort and one third also had asthma. Further data on the rate of recurrence leading to retreatment and associated costs are needed to understand the economic burden of CRSwNP in Canada.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3107.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021